Biotech and Pharmaceuticals Pharmaceuticals

  • Fiesta time started a little earlier than expected for investors in Eli Lilly, Amylin Pharmaceuticals and Alkermes. The companies had said they would file for Food and Drug Administration approval of the once-a-week version of the diabetes drug Byetta in the second quarter, but most analysts thought that meant June.

  • Whenever a politician, government agency or company puts out news late on a Friday chances are it probably isn't good or it's stuff they'd like to just slip under the door.

  • Dr. Susan Desmond-Hellmann

    Well, it didn't take long. A little more than a month after Roche swallowed Genentech, Dr. Susan Desmond-Hellmann may be headed out the door sooner than anyone thought.

  • cialis_050109_1.jpg

    have two reasons to exhale on this TGIF. My month-long stint on the graveyard shift anchoring "Worldwide Exchange" is over and Dendreon is done...for now. After all, Dendreon and its prostate cancer treatment Provenge is the story that just keeps on giving.

  • Sequenom

    Shares of San Diego-based Sequenom are sinking on huge trading volume. The company shocked investors after the closing bell yesterday when it issued this press release announcing that its data couldn't be trusted.

  • Investors can benefit from certain health care companies that will be boosted by the stimulus package, said Les Funtleyder, health care strategist of Miller Tabak.

  • Stocks advanced but ended off their highs Wednesday after the Federal Reserve said the recession appears to be easing.

  • dendreon.jpg

    The herky-jerky, stop-and-go cab ride I'm taking right now to O'Hare ain't nuthin' compared to yesterday's roller coaster ride at Chicago's McCormick Place. And can I just say? Is Dendreon  a giant magnet for high drama and intrigue or what?

  • Don't get so swept up in trying to predict where specific stocks are going that you ignore what they're saying about the market as a whole.

  • Futures pared gains Wednesday after the first look at first-quarter GDP showed the economy contracted at a sharper pace than expected.

  • How can a company that performed well during this recession be shunned by investors? Let Cramer explain.

  • flu_outbreak3.jpg

    Here we go again. When I was relatively new on this beat I was thrown into covering the bird flu scare. At the time, many experts said it wasn't a question of if, but when it would come to the U.S. I'm still waiting. And I hope we're all waiting forever.

  • Nasonex Ad

    I didn't have much of a weekend. I was putting out swine flu fires via work emails and dealing with a really bad allergy attack. Plus, it kinda gets cut short by having to go to bed so early (6 o'clock) in order to anchor "Worldwide Exchange" at 4 a.m. ET.

  • dendreon.jpg

    Next week's gonna be crazy, especially Tuesday aka "Dendreon Day." Shortly after I'm done anchoring "Worldwide Exchange" early Monday morning I'll be flying to Chicago to cover the highly anticipated data release on DNDN's Provenge. That's the name of the biotech company's unique, experimental treatment for prostate cancer.

  • pfizer_hq.jpg

    At Pfizer's annual shareholder meeting in Atlanta this morning, investors approved a version of "Say on Pay."

  • roche_logo.jpg

    It's a good thing I'm working the graveyard shift this month anchoring "Worldwide Exchange" at four o'clock in the morning. It was about the time that I woke up to go to work today at 1 a.m. ET that Roche and Genentech sent out their press releases announcing that their cancer drug Avastin didn't meet the main goal of a study to see if it extended the lives of people with early stage colon cancer.

  • Byetta Needle

    Shortly after Eli Lilly reported way better than expected earnings this morning, Amylin Pharmaceuticals fired a new salvo in its escalating proxy battle with billionaire activist investor Carl Icahn.

  • dendreon.jpg

    Not a surprise, but my post yesterday on what one reader called the analyst "flip-flop" on Dendreon generated a lot of responses and queries.

  • dendreon_logo_new.jpg

    As late as the day before the positive Dendreon data on its prostate cancer treatment Provenge came out, biotech analyst Jonathan Aschoff at Brean Murray Carret & Co. reiterated his "Sell" rating and $1 price target on the stock in a research note to clients. Today he's offering a bit of a mea culpa.

  • Investors are eager to hear results from Amylin and Biogen, Thursday. It seems the future of both firms could lie in the hands of Fast Money friend Carl Icahn!